477 related articles for article (PubMed ID: 25126672)
1. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.
Bosse T; Nout RA; Stelloo E; Dreef E; Nijman HW; Jürgenliemk-Schulz IM; Jobsen JJ; Creutzberg CL; Smit VT
Eur J Cancer; 2014 Oct; 50(15):2602-10. PubMed ID: 25126672
[TBL] [Abstract][Full Text] [Related]
2. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer--A pooled analysis of PORTEC 1 and 2 trials.
Bosse T; Peters EE; Creutzberg CL; Jürgenliemk-Schulz IM; Jobsen JJ; Mens JW; Lutgens LC; van der Steen-Banasik EM; Smit VT; Nout RA
Eur J Cancer; 2015 Sep; 51(13):1742-50. PubMed ID: 26049688
[TBL] [Abstract][Full Text] [Related]
3. L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation.
Zeimet AG; Reimer D; Huszar M; Winterhoff B; Puistola U; Azim SA; Müller-Holzner E; Ben-Arie A; van Kempen LC; Petru E; Jahn S; Geels YP; Massuger LF; Amant F; Polterauer S; Lappi-Blanco E; Bulten J; Meuter A; Tanouye S; Oppelt P; Stroh-Weigert M; Reinthaller A; Mariani A; Hackl W; Netzer M; Schirmer U; Vergote I; Altevogt P; Marth C; Fogel M
J Natl Cancer Inst; 2013 Aug; 105(15):1142-50. PubMed ID: 23781004
[TBL] [Abstract][Full Text] [Related]
4. Nomograms for prediction of outcome with or without adjuvant radiation therapy for patients with endometrial cancer: a pooled analysis of PORTEC-1 and PORTEC-2 trials.
Creutzberg CL; van Stiphout RG; Nout RA; Lutgens LC; Jürgenliemk-Schulz IM; Jobsen JJ; Smit VT; Lambin P
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):530-9. PubMed ID: 25680597
[TBL] [Abstract][Full Text] [Related]
5. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma.
Creutzberg CL; Nout RA; Lybeert ML; Wárlám-Rodenhuis CC; Jobsen JJ; Mens JW; Lutgens LC; Pras E; van de Poll-Franse LV; van Putten WL;
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e631-8. PubMed ID: 21640520
[TBL] [Abstract][Full Text] [Related]
6. L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer.
Pasanen A; Tuomi T; Isola J; Staff S; Bützow R; Loukovaara M
Int J Gynecol Cancer; 2016 Oct; 26(8):1465-71. PubMed ID: 27648714
[TBL] [Abstract][Full Text] [Related]
7. L1CAM as a prognostic marker in stage I endometrial cancer: a validation study.
Smogeli E; Davidson B; Cvancarova M; Holth A; Katz B; Risberg B; Kristensen G; Lindemann K
BMC Cancer; 2016 Aug; 16():596. PubMed ID: 27488577
[TBL] [Abstract][Full Text] [Related]
8. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial.
Nout RA; Smit VT; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Mens JW; Slot A; Kroese MC; van Bunningen BN; Ansink AC; van Putten WL; Creutzberg CL;
Lancet; 2010 Mar; 375(9717):816-23. PubMed ID: 20206777
[TBL] [Abstract][Full Text] [Related]
9. L1CAM: amending the "low-risk" category in endometrial carcinoma.
Kommoss F; Kommoss F; Grevenkamp F; Bunz AK; Taran FA; Fend F; Brucker SY; Wallwiener D; Schönfisch B; Greif K; Lax S; Staebler A; Kommoss S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):255-262. PubMed ID: 27695947
[TBL] [Abstract][Full Text] [Related]
10. L1CAM expression in endometrial carcinomas: an ENITEC collaboration study.
van der Putten LJ; Visser NC; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MP; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Amant F; Massuger LF; Pijnenborg JM
Br J Cancer; 2016 Sep; 115(6):716-24. PubMed ID: 27505134
[TBL] [Abstract][Full Text] [Related]
11. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study.
van der Putten LJM; Visser NCM; van de Vijver K; Santacana M; Bronsert P; Bulten J; Hirschfeld M; Colas E; Gil-Moreno A; Garcia A; Mancebo G; Alameda F; Trovik J; Kopperud RK; Huvila J; Schrauwen S; Koskas M; Walker F; Weinberger V; Minar L; Jandakova E; Snijders MPLM; van den Berg-van Erp S; Matias-Guiu X; Salvesen HB; Werner HMJ; Amant F; Massuger LFAG; Pijnenborg JMA
Int J Gynecol Cancer; 2018 Mar; 28(3):514-523. PubMed ID: 29324536
[TBL] [Abstract][Full Text] [Related]
12. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial.
Creutzberg CL; van Putten WL; Wárlám-Rodenhuis CC; van den Bergh AC; de Winter KA; Koper PC; Lybeert ML; Slot A; Lutgens LC; Stenfert Kroese MC; Beerman H; van Lent M;
J Clin Oncol; 2004 Apr; 22(7):1234-41. PubMed ID: 15051771
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
[TBL] [Abstract][Full Text] [Related]
14. L1CAM is an independent predictor of poor survival in endometrial cancer - An analysis of The Cancer Genome Atlas (TCGA).
Dellinger TH; Smith DD; Ouyang C; Warden CD; Williams JC; Han ES
Gynecol Oncol; 2016 May; 141(2):336-340. PubMed ID: 26861585
[TBL] [Abstract][Full Text] [Related]
15. L1 Cell Adhesion Molecule (L1CAM) expression in endometrioid endometrial carcinomas: A possible pre-operative surrogate of lymph vascular space invasion.
de Freitas D; Aguiar FN; Anton C; Bacchi CE; Carvalho JP; Carvalho FM
PLoS One; 2018; 13(12):e0209294. PubMed ID: 30557309
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant vaginal brachytherapy alone for high risk localized endometrial cancer as defined by the three major randomized trials of adjuvant pelvic radiation.
McCloskey SA; Tchabo NE; Malhotra HK; Odunsi K; Rodabaugh K; Singhal P; Lele S; Jaggernauth W
Gynecol Oncol; 2010 Mar; 116(3):404-7. PubMed ID: 19944453
[TBL] [Abstract][Full Text] [Related]
17. Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
Alektiar KM; Venkatraman E; Chi DS; Barakat RR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):111-7. PubMed ID: 15850910
[TBL] [Abstract][Full Text] [Related]
18. Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers.
Corrado G; Laquintana V; Loria R; Carosi M; de Salvo L; Sperduti I; Zampa A; Cicchillitti L; Piaggio G; Cutillo G; Falcioni R; Vizza E
J Exp Clin Cancer Res; 2018 Jul; 37(1):139. PubMed ID: 29980240
[TBL] [Abstract][Full Text] [Related]
19. Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy.
Wortman BG; Creutzberg CL; Putter H; Jürgenliemk-Schulz IM; Jobsen JJ; Lutgens LCHW; van der Steen-Banasik EM; Mens JWM; Slot A; Kroese MCS; van Triest B; Nijman HW; Stelloo E; Bosse T; de Boer SM; van Putten WLJ; Smit VTHBM; Nout RA;
Br J Cancer; 2018 Oct; 119(9):1067-1074. PubMed ID: 30356126
[TBL] [Abstract][Full Text] [Related]
20. Disseminated tumor cells are not associated with established risk factors, L1CAM immunoreactivity and outcome in endometrial carcinoma.
Kommoss S; Hartkopf AD; Krämer B; Bunz AK; Grevenkamp F; Kommoss F; Pasternak J; Arbabi SM; Wallwiener M; Staebler A; Lax SF; Brucker SY; Taran FA
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2183-2188. PubMed ID: 28710714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
